Wolfe Research has initiated coverage on Protagonist Therapeutics (NASDAQ: PTGX) with an outperform rating and a price target of $135, citing the company's strong early-stage pipeline and validated biology. The firm anticipates significant catalysts including clinical proof of concept for three wholly-owned assets by early 2027 and highlights potential milestone payments from partners Johnson & Johnson and Takeda. Other analysts from BMO Capital, Citizens, Jefferies, Truist Securities, and Clear Street have also expressed confidence in Protagonist Therapeutics, setting price targets between $116 and $137.
Protagonist Therapeutics (NASDAQ:PTGX) announced earnings results, reporting an EPS of $0.05, significantly beating analyst consensus estimates of ($0.65) by $0.70. The company's revenue reached $56.37 million, far surpassing the $12.21 million expected. Despite the strong earnings beat, the company remains unprofitable with a negative net margin and negative return on equity, and recent insider selling has been noted.
Protagonist Therapeutics reported a profitable first quarter of 2026, driven by a $50 million milestone payment for FDA approval of ICOTYDE and a strong cash position of $620.3 million. The company expects further revenue growth from its collaboration with Johnson & Johnson for ICOTYDE and from an amended agreement with Takeda for rusfertide, where Protagonist exercised its opt-out right, triggering a $200 million payment and future royalties. Despite increased R&D and general administrative expenses, the company's financial outlook is reshaped by these strategic milestones and deal restructuring.
